Bayer’s paper was subjected to extensive scrutiny by Morgan Stanley analyst Thibault Boutherin.
The US investment bank Morgan Stanley has left Bayer’s rating at “Equal-weight” with a price target of 52 euros following positive phase III study data for the drug Elinzanetant against menopausal symptoms. Positive results on hot flashes were expected, but the studies also reached the secondary endpoints with a view to fewer sleep disorders, wrote analyst Thibault Boutherin in a study available on Tuesday. The latter could be positive in terms of competition if approved as a drug./mis/ajx
From price target to trading volume: Bayer shares on the day of the detailed analysis
Bayer shares were up 1.0 percent at EUR 35.58 in the XETRA session at 12:51 p.m. The share therefore still has an upside potential of 46.17 percent based on the stated price target. Most recently, 1,549,445 Bayer shares changed hands via XETRA. Since the beginning of 2024, the share has risen by 5.8 percent. Bayer is expected to present its results for Q4 2023 on March 5, 2024.
NEW YORK (dpa-AFX Analyzer) / editorial team finanzen.net
Original study published: January 8, 2024 / 08:20 / GMT
First distribution of the original study: January 8, 2024 / time not specified in the study / time zone not specified in the study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 Para. 1 WpHG, Art. 20 Regulation (EU) 596/2014 for the analyst firm mentioned can be found at http://web.dpa-afx.de/offenstellenpflicht/ disclosure_duty.html.
Selected leverage products on Bayer
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Bayer
The leverage must be between 2 and 20
Advertising